
RAW SEQUENCE LISTING ERROR REPORT



The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number:	09/903,327	
Source:	0196	· · ·
Date Processed by STIC:	7/24/2001	

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.
PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION QUESTIONS, PLEASE CONTACT MARK SPENCER, 703-308-4212.

FOR SEQUENCE RULES INTERPRETATION, PLEASE CONTACT ROBERT WAX, 703-308-4216. PATENTIN 2.1 c-mail help: patin21help@uspto.gov or phone 703-306-4119 (R. Wax) PATENTIN 3.0 e-mail help: patin3help@uspto.gov or phone 703-306-4119 (R. Wax)

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE CHECKER VERSION 3.0 PROGRAM, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW:

Checker Version 3.0

The Checker Version 3.0 application is a state-of the-art Windows based software program employing a logical and intuitive user-interface to check whether a sequence listing is in compliance with format and content rules. Checker Version 3.0 works for sequence listings generated for the original version of 37 CFR §§1.821 – 1.825 effective October 1, 1990 (old rules) and the revised version (new rules) effective July 1, 1998 as well as World Intellectual Property Organization (WIPO) Standard ST.25.

Checker Version 3.0 replaces the previous DOS-based version of Checker, and is Y2K-compliant. Checker allows public users to check sequence listings in Computer Readable form (CRF) before submitting them to the United States Patent and Trademark Office (USPTO). Use of Checker prior to filing the sequence listing is expected to result in fewer errored sequence listings, thus saving time and money.

Checker Version 3.0 can be down loaded from the USPTO website at the following address: http://www.uspto.gov/web/offices/pac/checker

Raw Sequence Listing Error Summary

ERROR DETECTED	SUGGESTED CORRECTION SERIAL NUMBER: 09/903, 327
ATTN NEW RULES CASES	: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARI
Wrapped Nucleics Wrapped Aminos	The number/text at the end of each line "wrapped" down to the next line. This may occur if your file was retrieved in a word processor after creating it. Please adjust your right margin to .3; this will prevent "wrapping."
2Invalid Line Length	The rules require that a line not exceed 72 characters in length. This includes white spaces.
3Misaligned Amino Numbering	The numbering under each 5th amino acid is misaligned. Do not use tab codes between numbers; use space characters, instead.
4Non-ASCII	The submitted file was not saved in ASCII(DOS) text, as required by the Sequence Rules. Please ensure your subsequent submission is saved in ASCII text.
SVariable Length	Sequence(s)contain n's or Xaa's representing more than one residue. Per Sequence Rules, each n or Xaa can only represent a single residue. Please present the maximum number of each residue having variable length and indicate in the <220>-<223> section that some may be missing.
6PatentIn 2.0 "bug"	A "bug" in Patentln version 2.0 has caused the <220>-<223> section to be missing from amino acid sequences(s) Normally, Patentln would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence. This applies to the mandatory <220>-<223> sections for Artificial or Unknown sequences.
7Skipped Sequences (OLD RULES)	Sequence(s) missing. If intentional, please insert the following lines for each skipped sequence: (2) INFORMATION FOR SEQ ID NO:X: (insert SEQ ID NO where "X" is shown) (i) SEQUENCE CHARACTERISTICS: (Do not insert any subheadings under this heading) (xi) SEQUENCE DESCRIPTION:SEQ ID NO:X: (insert SEQ ID NO where "X" is shown) This sequence is intentionally skipped
	Please also adjust the "(ii) NUMBER OF SEQUENCES:" response to include the skipped sequences.
8Skipped Sequences (NEW RULES)	Sequence(s) missing. If intentional, please insert the following lines for each skipped sequence. <210> sequence id number <400> sequence id number 000
(NEW RULES)	Use of n's and/or Xaa's have been detected in the Sequence Listing. Per 1.823 of Sequence Rules, use of <220>-<223> is MANDATORY if n's or Xaa's are present. In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents.
Response	Per 1.823 of Sequence Rules, the only valid <213> responses are: Unknown, Artificial Sequence, or scientific name (Genus/species). <220>-<223> section is required when <213> response is Unknown or is Artificial Sequence
	Sequence(s) missing the <220> "Feature" and associated numeric identifiers and responses. Use of <220> to <223> is MANDATORY if <213> "Organism" response is "Artificial Sequence" or "Unknown." Please explain source of genetic material in <220> to <223> section. (See "Federal Register," 06/01/1998, Vol. 63, No. 104, pp. 29631-32) (Sec. 1.823 of Sequence Rules)
"bug"	Please do not use "Copy to Disk" function of Patentln version 2.0. This causes a corrupted file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing). Instead, please use "File Manager" or any other manual means to copy file to floppy disk.

AMC - Biotechnology Systems Branch - 06/04/2001

OIPE

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/903,327

DATE: 07/24/2001

TIME: 11:08:21

Input Set : A:\es.txt

Output Set: N:\CRF3\07242001\I903327.raw

Does Not Comply Corrected Diskette Needed

3 <110> APPLICANT: Nemerow, Glen R.

Li, Erquanq

6 <120> TITLE OF INVENTION: BIFUNCTIONAL MOLECULES AND VECTORS COMPLEXED THEREWITH FOR

TARGETED 7

GENE

8 DELIVERY

10 <130> FILE REFERENCE: 22908-1228

> 12 <140> CURRENT APPLICATION NUMBER: US/09/903,327

13 <141> CURRENT FILING DATE: 2001-07-10

lebete- just skow prior served no. 15 <150> PRIOR APPLICATION NUMBER: converted

16 <151> PRIOR FILING DATE: 2000-07-10

18 <160> NUMBER OF SEQ ID NOS: 33

20 <170> SOFTWARE: FastSEQ for Windows Version 4.0

ERRORED SEQUENCES

22	<210>	SEQ ID NO: 1	
23	<211>	LENGTH: 1516	\cap
24	<212>	TYPE: DNA	G. 7
25	<213>	ORGANISM: Mouse	(/ . 0
27	<220>	FEATURE:	- 11
28	<221>	NAME/KEY: CDS	V
29	<222>	LOCATION: (28)(1395)	
20	-222	OMITED INFORMATION. DAM	1 beeres abeda

30 <223> OTHER INFORMATION: DAV-1 heavy chain, penton base monoclonal antibody

32 <400> SEQUENCE: 1

33 cagacactga acacactgac tetaacc atg gga tgg agc tgg atc ttt etc ttc 34 Met Gly Trp Ser Trp Ile Phe Leu Phe 35 1 5 37 ctc ctq tca qqa act qca qqc qtc cac tct qaq qtc caq ctt caq caq 102

38 Leu Leu Ser Gly Thr Ala Gly Val His Ser Glu Val Gln Leu Gln Gln 15 20 41 tea gga eet gag etg gtg aaa eet ggg gee tea gtg aag ata tee tge 150

42 Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys 30 35

198 45 aag get tet gga tae aca tte act gae tae aac atg eac tgg gtg aag 46 Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr Asn Met His Trp Val Lys

47 45 49 cag agc cat gga aag agc ctt gag tgg att gga tat att tat cct tac 246 50 Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Tyr Ile Tyr Pro Tyr

65 53 aaa ggt ggt act ggc tac aac cag aag ttc aag agc aag gcc aca ttg

294 54 Lys Gly Gly Thr Gly Tyr Asn Gln Lys Phe Lys Ser Lys Ala Thr Leu 75 80 85 342

57 aca aca gac agt tee tee aac aca gee tae atg gag ete ege age etg 58 Thr Thr Asp Ser Ser Ser Asn Thr Ala Tyr Met Glu Leu Arg Ser Leu 95 100

61 aca tot gat goo tot goa gto tat tac tgt goa aga ggg att got tac 390 RAW SEQUENCE LISTING DATE: 07/24/2001
PATENT APPLICATION: US/09/903,327 TIME: 11:08:21

Input Set : A:\es.txt

Output Set: N:\CRF3\07242001\I903327.raw

	62 63	Thr	Ser	Asp	Ala	Ser 110	Ala	Val	Tyr	Tyr	Cys 115	Ala	Arg	Gly	Ile	Ala 120	Tyr	
		taa	aac	саа	aaa		cta	atc	act	gtc		aca	acc	222	aca		CCC	438
										Val								450
	67	115	Ory	OIII	125	1111	шси	vai	1111	130	DCI	niu	AIU	цуз	135	1111	LIO	
		cca	tet	atc		cca	cta	acc	cct	gga	tct	act	acc	caa		aac	tcc	486
										Gly								400
	71	110	DCI	140	1 Y L	110	Licu	ALU	145	OLY	DCI	niu	niu	150	1111	ASII	Der	
		ato	ata		cta	aaa	tac	cta		aag	aac	tat	ttc		σασ	cca	ata	534
					_		-	_	-	Lys								334
	75	ricc	155	1111	пси	GLY	Cys	160	VUI	цуз	Сту	тут	165	110	Giu	rio	Val	•
		aca		acc	taa	aac	tct		tcc	ctg	tcc	age		ata	cac	acc	ttc	582
										Leu								302
		170	va.	1111	111	non	175	Gry	DCI	пси	Der	180	GLY	Vai	1113	1111	185	
			act	atc	cta	can		aac	ctc	tac	act		agg	agg	tca	ata		630
			-	-	-	_		-		Tyr		_	_	-				030
	83	110	Alu	Vul	пец	190	Jer.	кэр	пеа	1 y 1	195	neu	DET	Del	Der	200	1111	
		atc	000	tcc	age		taa	ccc	agg	gag		ata	200	tac	220		acc	678
										Glu								070
	87	Val	110	561	205	1111	тър	FIO	DCI	210	1111	Val	1111	Суз	215	Val	Ald	
		cac	cca	acc		age	acc	aaσ	ata	gac	aarr	222	att	ata		add	gat	726
										Asp								720
	91	1113	110	220	Der	Jei	1111	цуз	225	пор	цуз	цуз	116	230	rio	ALG	изр	~
E>		tat	aat		aan	cct	tac	ata		aca	atc	cca	ma a		tca	tet	atc	(765)774
_ ,										Ťhr								(1)
	95	010	235	O _I U			O _I O	240	010				245		001	501	, 41	
		t.t.c		ttc	ccc	cca	aaσ		ааσ	gat	ata	ata		att	act	cta	act	822
										Asp								022
		250					255		-1-			260					265	
			aac	rato	acq	tat	att	. ata	gta	αac	ato		aac	r dat	gat	. ccc	gag	870
																	Ğlu	
	103		_			270				•	275		_		-	280		
			caq	tto	ago	tgg	ttt	gta	gat	gat	gtq	gad	qto	cac	aca	gct	cag	918
																	Gln	
	107				285	_			_	290					295			
	109	acg	caa	ccc	cgg	gag	gag	cag	ttc	aac	ago	act	tto	cgc	tca	gto	agt	966
	110	Thr	Glr	Pro	Arg	Glu	Glu	Gln	Phe	a Asn	Ser	Thi	Phe	Arg	ser [Val	Ser	
	111			300	I				305	5				310)			
	113	gaa	ctt	ccc	atc	atg	cac	cag	gac	: tgg	cto	aat	ggc	aag	gag	tto	aaa	1014
	114	Glu	Leu	Pro	Ile	Met	His	Gln	Asp	Trp	Leu	ı Asr	Gly	Lys	Glu	Phe	Lys	
	115		315					320					325					
	117	tgc	agg	gto	aac	agt	gca	gct	ttc	cct	gcc	ccc	ato	gag	aaa	acc	atc	1062
	118	Cys	Arg	Val	Asn	Ser	· Ala	Ala	Phe	Pro	Ala	Pro	Ile	Glu	Lys	Thr	Ile	
	119	330					335					340)				345	
	121	tcc	aaa	acc	aaa	ggc	aga	ccg	aag	gct	сса	cag	gtg	tac	acc	att	cca	1110
																	Pro	
	123					350					355					360		
																	atg	1158
	126	Pro	Pro	Lys	Glu	Gln	Met	Ala	Lys	Asp	Lys	Val	Ser	Leu	Thr	Cys	Met	

RAW SEQUENCE LISTING DATE: 07/24/2001 PATENT APPLICATION: US/09/903,327 TIME: 11:08:21

Input Set : A:\es.txt

Output Set: N:\CRF3\07242001\1903327.raw

127 365 370 375	
129 ata aca gac ttc ttc cct gaa gac att act gtg gag tgg cag tgg aat	1206
130 Ile Thr Asp Phe Phe Pro Glu Asp Ile Thr Val Glu Trp Gln Trp Asn	1200
131 380 385 390	
133 ggg cag cca gcg gag aac tac aag aac act cag ccc atc atg gac aca	1254
134 Gly Gln Pro Ala Glu Asn Tyr Lys Asn Thr Gln Pro Ile Met Asp Thr	1201
135 395 400 405	
137 gat ggc tct tac ttc gtc tac agc aag ctc aat gtg cag aag agc aac	1302
138 Asp Gly Ser Tyr Phe Val Tyr Ser Lys Leu Asn Val Gln Lys Ser Asn	1302
139 410 415 420 425	
141 tgg gag gca gga aat act ttc atc tgc tct.gtg tta cat gag ggc ctg	1350
142 Trp Glu Ala Gly Asn Thr Phe Ile Cys Ser Val Leu His Glu Gly Leu	1330
142 Trp Gra Ara Gry Ash Thir File Tre Cys Ser Var hea his Gra Gry hea 143 430 435 440	
145 cac aac cac cat act gag aag agc ctc tcc cac tct cct ggt aaa	1395
146 His Asn His His Thr Glu Lys Ser Leu Ser His Ser Pro Gly Lys	1393
140 HIS ASI HIS HIS HII GIU LYS SEI LEU SEI HIS SEI PIO GIY LYS 147 445 450 455	
	1455
149 tgatcccagt gtccttggag ccctctggtc ctacaggact ctgtcaccta cctccacccc 150 tccctgtata aataaagcac ctagcactgc cttgggaccc tgcaataaaa aaaaaaaaaa	1515
151 a	1516
705 (010) 770 770 70 10	1310
735 <210> SEQ ID NO: 12 736 <211> LENGTH: 510	
737 <211> TYPE: PRT	
738 <213> ORGANISM: Artificial Sequence	
740 <220> FEATURE:	
	DAVI-1 hoarm chain
741 <223> OTHER INFORMATION: Fusion protein with N-terminal portion of	DAV-1 heavy chain
742 and IGF-1 mature peptide	DAV-1 heavy chain
742 and IGF-1 mature peptide 744 <400> SEQUENCE: 12	DAV-1 heavy chain
742 and IGF-1 mature peptide 744 <400> SEQUENCE: 12 745 Met Gly Trp Ser Trp Ile Phe Leu Phe Leu Leu Ser Gly Thr Ala Gly	DAV-1 heavy chain
742 and IGF-1 mature peptide 744 <400> SEQUENCE: 12 745 Met Gly Trp Ser Trp Ile Phe Leu Phe Leu Leu Ser Gly Thr Ala Gly 746 1 5 10 15	DAV-1 heavy chain
742 and IGF-1 mature peptide 744 <400> SEQUENCE: 12 745 Met Gly Trp Ser Trp Ile Phe Leu Phe Leu Leu Ser Gly Thr Ala Gly 746 1 5 10 15 747 Val His Ser Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys	DAV-1 heavy chain
742 and IGF-1 mature peptide 744 <400> SEQUENCE: 12 745 Met Gly Trp Ser Trp Ile Phe Leu Phe Leu Leu Ser Gly Thr Ala Gly 746 1 5 10 15 747 Val His Ser Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys 748 20 25 30	DAV-1 heavy chain
742 and IGF-1 mature peptide 744 <400> SEQUENCE: 12 745 Met Gly Trp Ser Trp Ile Phe Leu Phe Leu Leu Ser Gly Thr Ala Gly 746 1 5 10 15 747 Val His Ser Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys 748 20 25 30 749 Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe	DAV-1 heavy chain
742 and IGF-1 mature peptide 744 <400> SEQUENCE: 12 745 Met Gly Trp Ser Trp Ile Phe Leu Phe Leu Leu Ser Gly Thr Ala Gly 746 1 5 10 15 747 Val His Ser Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys 748 20 25 30 749 Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe 750 35 40 45	DAV-1 heavy chain
742 and IGF-1 mature peptide 744 <400> SEQUENCE: 12 745 Met Gly Trp Ser Trp Ile Phe Leu Phe Leu Leu Ser Gly Thr Ala Gly 746 1 5 10 15 747 Val His Ser Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys 748 20 25 30 749 Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe 750 35 40 45 751 Thr Asp Tyr Asn Met His Trp Val Lys Gln Ser His Gly Lys Ser Leu	DAV-1 heavy chain
742 and IGF-1 mature peptide 744 <400> SEQUENCE: 12 745 Met Gly Trp Ser Trp Ile Phe Leu Phe Leu Leu Ser Gly Thr Ala Gly 746 1 5 10 15 747 Val His Ser Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys 748 20 25 30 749 Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe 750 35 40 45 751 Thr Asp Tyr Asn Met His Trp Val Lys Gln Ser His Gly Lys Ser Leu 752 50 55 60	DAV-1 heavy chain
742 and IGF-1 mature peptide 744 <400> SEQUENCE: 12 745 Met Gly Trp Ser Trp Ile Phe Leu Phe Leu Leu Ser Gly Thr Ala Gly 746 1 5 10 15 747 Val His Ser Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys 748 20 25 30 749 Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe 750 35 40 45 751 Thr Asp Tyr Asn Met His Trp Val Lys Gln Ser His Gly Lys Ser Leu 752 50 55 60 753 Glu Trp Ile Gly Tyr Ile Tyr Pro Tyr Lys Gly Gly Thr Gly Tyr Asn	DAV-1 heavy chain
742 and IGF-1 mature peptide 744 <400> SEQUENCE: 12 745 Met Gly Trp Ser Trp Ile Phe Leu Phe Leu Leu Ser Gly Thr Ala Gly 746 1 5 10 15 747 Val His Ser Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys 748 20 25 30 749 Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe 750 35 40 45 751 Thr Asp Tyr Asn Met His Trp Val Lys Gln Ser His Gly Lys Ser Leu 752 50 55 60 753 Glu Trp Ile Gly Tyr Ile Tyr Pro Tyr Lys Gly Gly Thr Gly Tyr Asn 754 65 70 75 80	DAV-1 heavy chain
742 and IGF-1 mature peptide 744 <400> SEQUENCE: 12 745 Met Gly Trp Ser Trp Ile Phe Leu Phe Leu Leu Ser Gly Thr Ala Gly 746 1 5 10 15 747 Val His Ser Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys 748 20 25 30 749 Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe 750 35 40 45 751 Thr Asp Tyr Asn Met His Trp Val Lys Gln Ser His Gly Lys Ser Leu 752 50 55 60 753 Glu Trp Ile Gly Tyr Ile Tyr Pro Tyr Lys Gly Gly Thr Gly Tyr Asn 754 65 70 75 80 755 Gln Lys Phe Lys Ser Lys Ala Thr Leu Thr Thr Asp Ser Ser Ser Asn	DAV-1 heavy chain
742 and IGF-1 mature peptide 744 <400> SEQUENCE: 12 745 Met Gly Trp Ser Trp Ile Phe Leu Phe Leu Leu Ser Gly Thr Ala Gly 746 1 5 10 15 747 Val His Ser Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys 748 20 25 30 749 Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe 750 35 40 45 751 Thr Asp Tyr Asn Met His Trp Val Lys Gln Ser His Gly Lys Ser Leu 752 50 55 60 753 Glu Trp Ile Gly Tyr Ile Tyr Pro Tyr Lys Gly Gly Thr Gly Tyr Asn 754 65 70 75 80 755 Gln Lys Phe Lys Ser Lys Ala Thr Leu Thr Thr Asp Ser Ser Ser Asn 756 85	DAV-1 heavy chain
742 and IGF-1 mature peptide 744 <400> SEQUENCE: 12 745 Met Gly Trp Ser Trp Ile Phe Leu Phe Leu Leu Ser Gly Thr Ala Gly 746 1 5 10 15 747 Val His Ser Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys 748 20 25 30 749 Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe 750 35 40 40 45 751 Thr Asp Tyr Asn Met His Trp Val Lys Gln Ser His Gly Lys Ser Leu 752 50 55 60 753 Glu Trp Ile Gly Tyr Ile Tyr Pro Tyr Lys Gly Gly Thr Gly Tyr Asn 754 65 70 75 80 755 Gln Lys Phe Lys Ser Lys Ala Thr Leu Thr Thr Asp Ser Ser Ser Asn 756 85 90 95 757 Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Asp Ala Ser Ala Val	DAV-1 heavy chain
742 and IGF-1 mature peptide 744 <400> SEQUENCE: 12 745 Met Gly Trp Ser Trp Ile Phe Leu Phe Leu Leu Ser Gly Thr Ala Gly 746 1	DAV-1 heavy chain
742 and IGF-1 mature peptide 744 <400> SEQUENCE: 12 745 Met Gly Trp Ser Trp Ile Phe Leu Phe Leu Leu Ser Gly Thr Ala Gly 746 1 5 10 15 747 Val His Ser Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys 748 20 25 30 749 Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe 750 35 40 45 751 Thr Asp Tyr Asn Met His Trp Val Lys Gln Ser His Gly Lys Ser Leu 752 50 55 60 753 Glu Trp Ile Gly Tyr Ile Tyr Pro Tyr Lys Gly Gly Thr Gly Tyr Asn 754 65 70 75 80 755 Gln Lys Phe Lys Ser Lys Ala Thr Leu Thr Thr Asp Ser Ser Ser Asn 756 85 90 95 757 Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Asp Ala Ser Ala Val 758 Tyr Tyr Cys Ala Arg Gly Ile Ala Tyr Trp Gly Gln Gly Thr Leu Val	DAV-1 heavy chain
742 and IGF-1 mature peptide 744 <400> SEQUENCE: 12 745 Met Gly Trp Ser Trp Ile Phe Leu Phe Leu Leu Ser Gly Thr Ala Gly 746 1 5 10 15 747 Val His Ser Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys 748 20 25 30 749 Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe 750 35 40 45 751 Thr Asp Tyr Asn Met His Trp Val Lys Gln Ser His Gly Lys Ser Leu 752 50 55 60 753 Glu Trp Ile Gly Tyr Ile Tyr Pro Tyr Lys Gly Gly Thr Gly Tyr Asn 754 65 70 70 75 80 755 Gln Lys Phe Lys Ser Lys Ala Thr Leu Thr Thr Asp Ser Ser Ser Asn 756 85 90 95 757 Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Asp Ala Ser Ala Val 758 Tyr Tyr Cys Ala Arg Gly Ile Ala Tyr Trp Gly Gln Gly Thr Leu Val 760 115	DAV-1 heavy chain
742 and IGF-1 mature peptide 744 <400> SEQUENCE: 12 745 Met Gly Trp Ser Trp Ile Phe Leu Phe Leu Leu Ser Gly Thr Ala Gly 746 1 5 10 15 747 Val His Ser Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys 748 20 25 30 749 Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe 750 35 40 45 751 Thr Asp Tyr Asn Met His Trp Val Lys Gln Ser His Gly Lys Ser Leu 752 50 55 60 753 Glu Trp Ile Gly Tyr Ile Tyr Pro Tyr Lys Gly Gly Thr Gly Tyr Asn 754 65 70 75 80 755 Gln Lys Phe Lys Ser Lys Ala Thr Leu Thr Thr Asp Ser Ser Ser Asn 756 85 90 95 757 Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Asp Ala Ser Ala Val 758 Tyr Tyr Cys Ala Arg Gly Ile Ala Tyr Trp Gly Gln Gly Thr Leu Val 760 115 120 770 Ser Val Tyr Pro Leu Ala	DAV-1 heavy chain
742 and IGF-1 mature peptide 744 <400> SEQUENCE: 12 745 Met Gly Trp Ser Trp Ile Phe Leu Phe Leu Leu Ser Gly Thr Ala Gly 746 1 5 10 15 747 Val His Ser Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys 748 20 25 30 749 Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe 750 35 40 45 751 Thr Asp Tyr Asn Met His Trp Val Lys Gln Ser His Gly Lys Ser Leu 752 50 55 60 753 Glu Trp Ile Gly Tyr Ile Tyr Pro Tyr Lys Gly Gly Thr Gly Tyr Asn 754 65 70 70 75 80 755 Gln Lys Phe Lys Ser Lys Ala Thr Leu Thr Asp Ser Ser Ser Asn 756 Gln Lys Phe Glu Leu Arg Ser Leu Thr Ser Asp Ala Ser Ala Val 758 Tyr Tyr Cys Ala Arg Gly Ile Ala Tyr Trp Gly Gln Gly Thr Leu Val 759 Tyr Tyr Cys Ala Arg Gly Ile Ala Tyr Trp Gly Gln Gly Thr Leu Val 760 115 120 125 761 Thr Val Ser Ala Ala Lys Thr Thr Pro Pro Ser Val Tyr Pro Leu Ala 762 130 135	DAV-1 heavy chain
742 and IGF-1 mature peptide 744 <400> SEQUENCE: 12 745 Met Gly Trp Ser Trp Ile Phe Leu Phe Leu Leu Ser Gly Thr Ala Gly 10 15 746 1 5 10 15 747 Val His Ser Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys 20 25 30 749 Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe 35 40 45 751 Thr Asp Tyr Asn Met His Trp Val Lys Gln Ser His Gly Lys Ser Leu 55 60 753 Glu Trp Ile Gly Tyr Ile Tyr Pro Tyr Lys Gly Gly Thr Gly Tyr Asn 75 60 755 Gln Lys Phe Lys Ser Lys Ala Thr Leu Thr Thr Asp Ser Ser Ser Asn 90 95 757 Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Asp Ala Ser Ala Val 105 100 759 Tyr Tyr Cys Ala Arg Gly Ile Ala Tyr Trp Gly Gln Gly Thr Leu Val 125 120 761 Thr Val Ser Ala Ala Ala Lys Thr Thr Pro Pro Ser Val Tyr Pro Leu Ala 130 135 763 Pro Gly Ser Ala Ala Ala Gln Thr Asn Ser Met Val Thr Leu Gly Cys Leu	DAV-1 heavy chain
742 and IGF-1 mature peptide 744 <400> SEQUENCE: 12 745 Met Gly Trp Ser Trp Ile Phe Leu Phe Leu Leu Ser Gly Thr Ala Gly 746 1	DAV-1 heavy chain
742 and IGF-1 mature peptide 744 <400> SEQUENCE: 12 745 Met Gly Trp Ser Trp Ile Phe Leu Phe Leu Leu Ser Gly Thr Ala Gly 10 15 746 1 5 10 15 747 Val His Ser Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys 20 25 30 749 Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe 35 40 45 751 Thr Asp Tyr Asn Met His Trp Val Lys Gln Ser His Gly Lys Ser Leu 55 60 753 Glu Trp Ile Gly Tyr Ile Tyr Pro Tyr Lys Gly Gly Thr Gly Tyr Asn 75 60 755 Gln Lys Phe Lys Ser Lys Ala Thr Leu Thr Thr Asp Ser Ser Ser Asn 90 95 757 Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Asp Ala Ser Ala Val 105 100 759 Tyr Tyr Cys Ala Arg Gly Ile Ala Tyr Trp Gly Gln Gly Thr Leu Val 125 120 761 Thr Val Ser Ala Ala Ala Lys Thr Thr Pro Pro Ser Val Tyr Pro Leu Ala 130 135 763 Pro Gly Ser Ala Ala Ala Gln Thr Asn Ser Met Val Thr Leu Gly Cys Leu	DAV-1 heavy chain

RAW SEQUENCE LISTING DATE: 07/24/2001 PATENT APPLICATION: US/09/903,327 TIME: 11:08:21

Input Set : A:\es.txt

Output Set: N:\CRF3\07242001\I903327.raw

```
767 Ser Leu Ser Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Asp
               180
                                   185
769 Leu Tyr Thr Leu Ser Ser Val Thr Val Pro Ser Ser Thr Trp Pro
                               200
    195
771 Ser Glu Thr Val Thr Cys Asn Val Ala His Pro Ala Ser Ser Thr Lys
                           215
773 Val Asp Lys Lys Ile Val Pro Arg Asp Cys Gly Cys Lys Pro Cys Ile
                       230
                                           235
775 Cys Thr Val Pro Glu Val Ser Ser Val Phe Ile Phe Pro Pro Lys Pro
                   245
                                       250
777 Lys Asp Val Leu Thr Ile Thr Leu Thr Pro Lys Val Thr Cys Val Val
               260
                                   265
779 Val Asp Ile Ser Lys Asp Asp Pro Glu Val Gln Phe Ser Trp Phe Val
                               280
781 Asp Asp Val Glu Val His Thr Ala Gln Thr Gln Pro Arg Glu Glu Gln
                           295
783 Phe Asn Ser Thr Phe Arg Ser Val Ser Glu Leu Pro Ile Met His Gln
                       310
                                           315
785 Asp Trp Leu Asn Gly Lys Glu Phe Lys Cys Arg Val Asn Ser Ala Ala
                  325
                                       330
787 Phe Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Thr Lys Gly Arg Pro
               340
                                   345
789 Lys Ala Pro Gln Val Tyr Thr Ile Pro Pro Pro Lys Glu Gln Met Ala
791 Lys Asp Lys Val Ser Leu Thr Cys Met Ile Thr Asp Phe Phe Pro Glu
792 · 370
                           375
793 Asp Ile Thr Val Glu Trp Gln Trp Asn Gly Gln Pro Ala Glu Asn Tyr
                       390
                                           395
795 Lys Asn Thr Gln Pro Ile Met Asp Thr Asp Gly Ser Tyr Phe Val Tyr
                   405
                                       410
797 Ser Lys Leu Asn Val Gln Lys Ser Asn Trp Glu Ala Gly Asn Thr Phe
               420
                                   425
799 Ile Cys Ser Val Leu His Glu Phe Gly Pro Glu Thr Leu Cys Gly Ala
    435
                               440
801 Glu Leu Val Asp Ala Leu Gln Phe Val Cys Gly Asp Arg Gly Phe Tyr
                           455
                                               460
803 Phe Asn Lys Pro Thr Gly Tyr Gly Ser Ser Arg Arg Ala Pro Gln
                       470
                                           475
805 Thr Gly Ile Val Asp Glu Cys Cys Phe Arg Ser Cys Asp Leu Arg Arg
                  485
                                       490
                                                     Sio C present number
807 Leu Glu Met Tyr Cys Ala Pro Leu Lys Pro Ala Lys Ser Ala
               500
                                   505
1156 <210> SEQ ID NO: 30
1157 <211> LENGTH: 96
                                                  next roger
1158 <212> TYPE: DNA
1159 <213> ORGANISM: Artificial Sequence
1161 <220> FEATURE:
1162 <223> OTHER INFORMATION: PCR sense primer for subcloning EGF into DAV-1/EGF
          fusion construct.
```

RAW SEQUENCE LISTING

DATE: 07/24/2001

PATENT APPLICATION: US/09/903,327

TIME: 11:08:21

Input Set : A:\es.txt

Output Set: N:\CRF3\07242001\1903327.raw

Journal even see n Even furmour Sheet

1165 <400> SEQUENCE: 30

E--> 1166 gaattcaata gtgactctga atgtcccctg tcccacgatg ggtactgcct ccatgatggt 60 -

60 ~

1167

1168 gtgtgcatgt atattgaagc attggacaag tatgca

1170 <210> SEQ ID NO: 31

1171 <211> LENGTH: 98

1172 <212> TYPE: DNA

1173 <213> ORGANISM: Artificial Sequence

1175 <220> FEATURE:

1176 <223> OTHER INFORMATION: PCR antisense primer for subcloning EGF into DAV-1/EGF

fusion construct.

1179 <400> SEQUENCE: 31

E--> 1180 gaattetage geagtteeea ceaetteagg teteggtaet gaeategete eeegatgtag 🥱 60

1182 ccaacaacac agttgcatgc atacttgtcc aatgcttc

98

VERIFICATION SUMMARY

PATENT APPLICATION: US/09/903,327

DATE: 07/24/2001 TIME: 11:08:22

Input Set : A:\es.txt

Output Set: N:\CRF3\07242001\1903327.raw

L:12 M:270 C: Current Application Number differs, Replaced Current Application Number

L:93 M:254 E: No. of Bases conflict, LENGTH:Input:765 Counted:774 SEQ:1

L:350 M:351 W: Sequence data Name/Key Feature Out-of-Range, SEQ ID#:5, CDS LOCATION: (0)...

(1314)

L:808 M:332 E: (32) Invalid/Missing Amino Acid Numbering, SEQ ID:12 L:1166 M:254 E: No. of Bases conflict, LENGTH:Input:0 Counted:60 SEQ:30 L:1180 M:254 E: No. of Bases conflict, LENGTH:Input:0 Counted:60 SEQ:31